JP2017535609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535609A5 JP2017535609A5 JP2017544993A JP2017544993A JP2017535609A5 JP 2017535609 A5 JP2017535609 A5 JP 2017535609A5 JP 2017544993 A JP2017544993 A JP 2017544993A JP 2017544993 A JP2017544993 A JP 2017544993A JP 2017535609 A5 JP2017535609 A5 JP 2017535609A5
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- group
- hgh
- alkyl
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000651 prodrug Substances 0.000 claims description 72
- 229940002612 prodrug Drugs 0.000 claims description 72
- 239000000854 Human Growth Hormone Substances 0.000 claims description 40
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 40
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 40
- 229920000642 polymer Polymers 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 16
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 15
- 206010056438 Growth hormone deficiency Diseases 0.000 claims description 14
- -1 R 10a Chemical compound 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 8
- 206010053759 Growth retardation Diseases 0.000 claims description 8
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 8
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 8
- 239000007983 Tris buffer Substances 0.000 claims description 8
- 208000020832 chronic kidney disease Diseases 0.000 claims description 8
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000001384 succinic acid Substances 0.000 claims description 8
- 229940074409 trehalose dihydrate Drugs 0.000 claims description 8
- 206010029748 Noonan syndrome Diseases 0.000 claims description 7
- 208000026928 Turner syndrome Diseases 0.000 claims description 7
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 239000012669 liquid formulation Substances 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 102000048489 Short Stature Homeobox Human genes 0.000 claims description 5
- 108700025071 Short Stature Homeobox Proteins 0.000 claims description 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 4
- 125000005916 2-methylpentyl group Chemical group 0.000 claims description 4
- 125000005917 3-methylpentyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 208000036119 Frailty Diseases 0.000 claims description 4
- 150000001412 amines Chemical group 0.000 claims description 4
- 206010003549 asthenia Diseases 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000001076 sarcopenia Diseases 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 238000012384 transportation and delivery Methods 0.000 claims description 4
- 206010064571 Gene mutation Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 239000012038 nucleophile Substances 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 206010041092 Small for dates baby Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- MLONYBFKXHEPCD-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO MLONYBFKXHEPCD-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020177083A JP6982156B2 (ja) | 2014-11-18 | 2020-10-22 | 新規hGHポリマープロドラッグ |
| JP2021187453A JP7210683B2 (ja) | 2014-11-18 | 2021-11-18 | 新規hGHポリマープロドラッグ |
| JP2023002061A JP7431355B2 (ja) | 2014-11-18 | 2023-01-11 | 新規hGHポリマープロドラッグ |
| JP2024013884A JP7785109B2 (ja) | 2014-11-18 | 2024-02-01 | 新規hGHポリマープロドラッグ |
| JP2025216658A JP2026041857A (ja) | 2014-11-18 | 2025-12-02 | 新規hGHポリマープロドラッグ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193603.9 | 2014-11-18 | ||
| EP14193603 | 2014-11-18 | ||
| PCT/EP2015/076813 WO2016079114A1 (en) | 2014-11-18 | 2015-11-17 | Novel polymeric hgh prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177083A Division JP6982156B2 (ja) | 2014-11-18 | 2020-10-22 | 新規hGHポリマープロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535609A JP2017535609A (ja) | 2017-11-30 |
| JP2017535609A5 true JP2017535609A5 (cg-RX-API-DMAC7.html) | 2020-04-09 |
| JP6783782B2 JP6783782B2 (ja) | 2020-11-11 |
Family
ID=51951624
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544993A Active JP6783782B2 (ja) | 2014-11-18 | 2015-11-17 | 新規hGHポリマープロドラッグ |
| JP2020177083A Active JP6982156B2 (ja) | 2014-11-18 | 2020-10-22 | 新規hGHポリマープロドラッグ |
| JP2021187453A Active JP7210683B2 (ja) | 2014-11-18 | 2021-11-18 | 新規hGHポリマープロドラッグ |
| JP2023002061A Active JP7431355B2 (ja) | 2014-11-18 | 2023-01-11 | 新規hGHポリマープロドラッグ |
| JP2024013884A Active JP7785109B2 (ja) | 2014-11-18 | 2024-02-01 | 新規hGHポリマープロドラッグ |
| JP2025216658A Pending JP2026041857A (ja) | 2014-11-18 | 2025-12-02 | 新規hGHポリマープロドラッグ |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177083A Active JP6982156B2 (ja) | 2014-11-18 | 2020-10-22 | 新規hGHポリマープロドラッグ |
| JP2021187453A Active JP7210683B2 (ja) | 2014-11-18 | 2021-11-18 | 新規hGHポリマープロドラッグ |
| JP2023002061A Active JP7431355B2 (ja) | 2014-11-18 | 2023-01-11 | 新規hGHポリマープロドラッグ |
| JP2024013884A Active JP7785109B2 (ja) | 2014-11-18 | 2024-02-01 | 新規hGHポリマープロドラッグ |
| JP2025216658A Pending JP2026041857A (ja) | 2014-11-18 | 2025-12-02 | 新規hGHポリマープロドラッグ |
Country Status (27)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3004716C (en) | 2008-04-29 | 2022-04-12 | Ascendis Pharma Endocrinology Division A/S | Pegylated recombinant human growth hormone compounds |
| EP2512450B1 (en) | 2009-12-15 | 2018-02-07 | Ascendis Pharma Endocrinology Division A/S | Dry growth hormone composition transiently linked to a polymer carrier |
| KR102608645B1 (ko) | 2014-11-18 | 2023-12-01 | 아센디스 파마 엔도크리놀로지 디비전 에이/에스 | 신규한 중합체성 hGH 프로드러그 |
| EP4732848A3 (en) * | 2014-11-21 | 2026-07-29 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
| CA3008015A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability |
| EP4710947A3 (en) | 2016-01-08 | 2026-06-17 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| RU2768747C2 (ru) * | 2016-09-29 | 2022-03-24 | Асцендис Фарма Гроус Дизордерс А/С | Комбинаторная терапия с агонистами cnp контролируемого высвобождения |
| CA3093083A1 (en) * | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Conjugates |
| US12565525B2 (en) | 2018-03-28 | 2026-03-03 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
| SG11202104966XA (en) | 2019-01-04 | 2021-06-29 | Ascendis Pharma Oncology Div A/S | Sustained local drug levels for innate immune agonists |
| AU2020205029A1 (en) | 2019-01-04 | 2021-06-24 | Ascendis Pharma Oncology Division A/S | Minimization of systemic inflammation |
| EP3906018A1 (en) | 2019-01-04 | 2021-11-10 | Ascendis Pharma Oncology Division A/S | Induction of sustained local inflammation |
| SG11202105835YA (en) | 2019-01-04 | 2021-07-29 | Ascendis Pharma Oncology Div A/S | Conjugates of pattern recognition receptor agonists |
| JP7524206B2 (ja) * | 2019-03-04 | 2024-07-29 | アセンディス ファーマ エンドクライノロジー ディヴィジョン エー/エス | 1日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形 |
| CA3178074A1 (en) | 2020-06-03 | 2021-12-09 | Nina Gunnarsson | Il-2 sequences and uses thereof |
| EP4314035A1 (en) * | 2021-04-01 | 2024-02-07 | Ascendis Pharma A/S | Use of long-acting growth hormone for treating inflammation-induced diseases |
| CA3237877A1 (en) * | 2021-11-12 | 2023-05-19 | Aditya JARARE | Novel formulation for drying of polymer dye conjugated antibodies |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| IL78930A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Lyophilized emulsion compositions for parenteral administration |
| US5057417A (en) | 1987-06-12 | 1991-10-15 | Genentech, Inc. | Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5179080A (en) | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
| JPH0531189A (ja) | 1991-01-16 | 1993-02-09 | Takeda Chem Ind Ltd | 2室型注射器 |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| IL101007A (en) | 1992-02-18 | 1997-08-14 | Pharmos Ltd | Dry stable compositions prepared by lyophilization |
| PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
| SE501808C2 (sv) | 1993-11-26 | 1995-05-22 | Hans Lundstroem | Anordning vid en box |
| ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| KR100236771B1 (ko) | 1997-04-01 | 2000-02-01 | 성재갑 | 히아루론산을 이용한 약물의 서방성 미세입자 제형 |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6011197A (en) * | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
| US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
| WO1999030727A1 (en) | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| JP4361710B2 (ja) | 2000-04-19 | 2009-11-11 | ジェネンテック・インコーポレーテッド | 徐放製剤 |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| OA13063A (en) | 2001-11-20 | 2006-11-10 | Pharmacia Corp | Chemically-modified human growth hormone conjugates. |
| US20030171285A1 (en) | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| US7144978B2 (en) | 2002-01-15 | 2006-12-05 | Pan Asia Bio Co., Ltd. | Multidrop tree branching functional polyethylene glycol, methods of preparing and using same |
| US20050271615A1 (en) | 2002-08-30 | 2005-12-08 | Doron Shabat | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| MXPA05005178A (es) | 2002-11-15 | 2005-07-22 | Hoffmann La Roche | Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg). |
| US20040142870A1 (en) | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| US7947261B2 (en) | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
| WO2005035553A2 (en) | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Conjugation of peptides |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| EP1579873A1 (en) * | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
| EP1625855A1 (en) * | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Polymeric prodrug with a self-immolative linker |
| CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| JP2008525032A (ja) | 2004-12-22 | 2008-07-17 | アンブレツクス・インコーポレイテツド | 組換えヒト成長ホルモンを発現及び精製するための方法 |
| CA2594557C (en) | 2004-12-22 | 2016-04-26 | Ambrx, Inc. | Modified human growth hormone |
| BRPI0519170A8 (pt) | 2004-12-22 | 2018-05-08 | Ambrx Inc | formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado |
| US7959600B2 (en) | 2004-12-30 | 2011-06-14 | Byeong S. Chang | Container closure delivery system |
| WO2006076471A2 (en) | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
| WO2006084888A2 (en) | 2005-02-10 | 2006-08-17 | Novo Nordisk A/S | C-terminally pegylated growth hormones |
| US20060233740A1 (en) * | 2005-03-23 | 2006-10-19 | Bossard Mary J | Conjugates of an hGH moiety and a polymer |
| BRPI0611570A2 (pt) | 2005-06-15 | 2011-02-22 | Novo Nordisk Healthcare Ag | métodos para fixar covalentemente peg a um polipeptìdeo e para modificar propriedades farmacológicas de hormÈnio de crescimento, composto e sais, pró-drogas ou solvatos farmaceuticamente aceitáveis do mesmo, hormÈnio de crescimento humano, composição farmacêutica, método para tratamento de doença e, uso de um composto |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| US8293708B2 (en) | 2005-08-30 | 2012-10-23 | Novo Nordisk Health Care A/G | Liquid formulations N-terminal serine of pegylated growth hormone |
| WO2007075534A2 (en) | 2005-12-16 | 2007-07-05 | Nektar Therapeutics Al, Corporation | Polymer conjugates of glp-1 |
| WO2007114881A1 (en) | 2006-01-24 | 2007-10-11 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| WO2008148839A2 (en) | 2007-06-08 | 2008-12-11 | Ascendis Pharma As | Long-acting polymeric prodrugs of exendin |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| LT2237799T (lt) | 2008-02-01 | 2019-07-25 | Ascendis Pharma A/S | Provaistas, apimantis besiskaidantį linkerį |
| EP2113256A1 (en) | 2008-04-29 | 2009-11-04 | Ascendis Pharma AS | PEGylated rhGH compounds |
| CA3004716C (en) | 2008-04-29 | 2022-04-12 | Ascendis Pharma Endocrinology Division A/S | Pegylated recombinant human growth hormone compounds |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| CN102413843A (zh) | 2009-03-05 | 2012-04-11 | 阿森迪斯药物股份有限公司 | 干扰素α载体前药 |
| WO2011003234A1 (zh) | 2009-07-08 | 2011-01-13 | 深圳市掌网立体时代视讯技术有限公司 | 光学立体放映装置、系统及方法 |
| US9173953B2 (en) | 2009-07-31 | 2015-11-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
| LT2459220T (lt) | 2009-07-31 | 2020-12-28 | Ascendis Pharma A/S | Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu |
| EP2512450B1 (en) * | 2009-12-15 | 2018-02-07 | Ascendis Pharma Endocrinology Division A/S | Dry growth hormone composition transiently linked to a polymer carrier |
| EP4450523A3 (en) | 2010-04-02 | 2025-03-12 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| DK2571510T3 (en) | 2010-05-21 | 2018-11-19 | Xl Protein Gmbh | BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS |
| WO2014060512A1 (en) | 2012-10-17 | 2014-04-24 | Novo Nordisk Health Care Ag | Fatty acid acylated amino acids for growth hormone delivery |
| KR102608645B1 (ko) | 2014-11-18 | 2023-12-01 | 아센디스 파마 엔도크리놀로지 디비전 에이/에스 | 신규한 중합체성 hGH 프로드러그 |
| EP4732848A3 (en) | 2014-11-21 | 2026-07-29 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
| WO2016109823A1 (en) | 2015-01-02 | 2016-07-07 | Amunix Operation Inc. | Treatment of pediatric growth hormone deficiency with human growth hormone analogues |
| JP7524206B2 (ja) | 2019-03-04 | 2024-07-29 | アセンディス ファーマ エンドクライノロジー ディヴィジョン エー/エス | 1日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形 |
-
2015
- 2015-11-17 KR KR1020177016287A patent/KR102608645B1/ko active Active
- 2015-11-17 FI FIEP15797642.4T patent/FI3237014T3/fi active
- 2015-11-17 IL IL326263A patent/IL326263A/en unknown
- 2015-11-17 ES ES19214864T patent/ES2864415T7/es active Active
- 2015-11-17 IL IL251906A patent/IL251906B2/en unknown
- 2015-11-17 CA CA2968282A patent/CA2968282C/en active Active
- 2015-11-17 SG SG11201703870UA patent/SG11201703870UA/en unknown
- 2015-11-17 KR KR1020257012690A patent/KR20250059541A/ko active Pending
- 2015-11-17 DK DK19214864.1T patent/DK3653227T5/da active
- 2015-11-17 ES ES15797642T patent/ES2947818T3/es active Active
- 2015-11-17 SI SI201531543T patent/SI3653227T1/sl unknown
- 2015-11-17 JP JP2017544993A patent/JP6783782B2/ja active Active
- 2015-11-17 SG SG10202105511RA patent/SG10202105511RA/en unknown
- 2015-11-17 EP EP19214864.1A patent/EP3653227B9/en active Active
- 2015-11-17 EP EP23164305.7A patent/EP4218823A3/en active Pending
- 2015-11-17 US US15/527,744 patent/US10799563B2/en active Active
- 2015-11-17 HU HUE19214864A patent/HUE053855T2/hu unknown
- 2015-11-17 LT LTEP19214864.1T patent/LT3653227T/lt unknown
- 2015-11-17 RS RS20210444A patent/RS61734B2/sr unknown
- 2015-11-17 HR HRP20210400TT patent/HRP20210400T4/hr unknown
- 2015-11-17 WO PCT/EP2015/076813 patent/WO2016079114A1/en not_active Ceased
- 2015-11-17 RU RU2017121203A patent/RU2718664C2/ru active
- 2015-11-17 MX MX2017006113A patent/MX394222B/es unknown
- 2015-11-17 CA CA3294730A patent/CA3294730A1/en active Pending
- 2015-11-17 KR KR1020237037045A patent/KR20230152187A/ko not_active Ceased
- 2015-11-17 PL PL19214864T patent/PL3653227T6/pl unknown
- 2015-11-17 AU AU2015348633A patent/AU2015348633C1/en active Active
- 2015-11-17 DK DK15797642.4T patent/DK3237014T5/da active
- 2015-11-17 PT PT192148641T patent/PT3653227T/pt unknown
- 2015-11-17 EP EP15797642.4A patent/EP3237014B1/en active Active
- 2015-11-17 SM SM20210172T patent/SMT202100172T1/it unknown
-
2017
- 2017-05-10 MX MX2022009155A patent/MX2022009155A/es unknown
-
2020
- 2020-08-28 US US17/006,589 patent/US12133883B2/en active Active
- 2020-10-22 JP JP2020177083A patent/JP6982156B2/ja active Active
- 2020-11-18 AU AU2020270494A patent/AU2020270494B2/en active Active
-
2021
- 2021-03-18 CY CY20211100235T patent/CY1123963T1/el unknown
- 2021-11-18 JP JP2021187453A patent/JP7210683B2/ja active Active
-
2022
- 2022-04-20 NL NL301172C patent/NL301172I2/nl unknown
- 2022-04-27 LU LU00256C patent/LUC00256I2/en unknown
- 2022-05-10 HU HUS2200019C patent/HUS2200019I1/hu unknown
- 2022-05-12 CY CY2022013C patent/CY2022013I1/el unknown
- 2022-05-12 NO NO2022014C patent/NO2022014I1/no unknown
- 2022-05-23 LT LTPA2022506C patent/LTC3653227I2/lt unknown
- 2022-06-03 FI FIC20220017C patent/FIC20220017I1/fi unknown
- 2022-06-10 FR FR22C1029C patent/FR22C1029I2/fr active Active
-
2023
- 2023-01-11 JP JP2023002061A patent/JP7431355B2/ja active Active
- 2023-10-16 IL IL307773A patent/IL307773B2/en unknown
-
2024
- 2024-02-01 JP JP2024013884A patent/JP7785109B2/ja active Active
- 2024-02-23 AU AU2024201227A patent/AU2024201227A1/en active Pending
- 2024-09-20 US US18/891,744 patent/US20250032587A1/en active Pending
-
2025
- 2025-12-02 JP JP2025216658A patent/JP2026041857A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017121203A (ru) | НОВЫЕ ПОЛИМЕРНЫЕ hGH ПРОЛЕКАРСТВА | |
| ES2943013T3 (es) | Terapia de combinación con agonistas del CNP de liberación controlada | |
| RU2017128291A (ru) | Cnp пролекарства | |
| TWI463991B (zh) | 生長抑素(somatostatin)或其類似物之持續釋放型藥學組成物 | |
| JP2021102643A5 (cg-RX-API-DMAC7.html) | ||
| ES2652114T3 (es) | Una disolución que contiene silicato para uso en el tratamiento de melanoma | |
| AU2025205514A1 (en) | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin | |
| JP2025500826A5 (cg-RX-API-DMAC7.html) | ||
| JP2024040213A (ja) | 高濃縮アルファ-1プロテイナーゼインヒビターを含む組成物及びそれを得るための方法 | |
| US20100261739A1 (en) | Method of Treating Non-Small Cell Lung Cancer | |
| ES2959804T3 (es) | Nueva formulación farmacéutica que comprende un modulador de STING | |
| RU2020109736A (ru) | НОВЫЕ ПОЛИМЕРНЫЕ hGH ПРОЛЕКАРСТВА | |
| KR20130141998A (ko) | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 | |
| WO2017211273A1 (en) | Dsg2-derived peptides | |
| WO2018024873A1 (en) | Pharmaceutical formulations of c1 esterase inhibitor | |
| BR112017009798B1 (pt) | Pro-fármacos de hgh poliméricos, formulações farmacêuticas líquidas, secas e reconstituídas, método de preparação da referida formulação reconstituída bem como uso do referido profármaco | |
| JP2007126363A (ja) | グリチルリチン製剤 | |
| TW201740929A (zh) | 蛋白酶抑製劑之長效醫藥組合物 | |
| HK1240819A1 (en) | Novel polymeric hgh prodrugs | |
| HK1240819B (en) | Novel polymeric hgh prodrugs |